Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

ECB. 2022; 11(8): 152-156


EVALUATION OF SERUM RESISTIN IN OBESE TYPE TWO DIABETES MELLITUS PATIENTS IN MOSUL CITY, IRAQ

Dr. Zinah M Al-Yozbakee, Dr. Niaam N Jammil, Dr. Nada N Fadhil.




Abstract

Obesity is a dangerous health concern; and nowadays it becomes epidemic. It is a target factor for many diseases
including type 2 diabetes mellitus (T2DM). Adepokines are factors secreted from adipose tissue that affect many organs' function.
One of these adepokines is resistin. Resistin acts as a proinflammatory adepokine as it induces secretion of "tumor necrosis factor
alpha and interlukin-6" and mediates insulin resistance. In this study the level of fasting serum resistin, insulin, and C-reactive
protein (CRP) has been estimated, and the insulin resistance has been calculated by HOMA-IR for three groups: group one “thirty
obese patients who had T2DM”, group two “thirty obese healthy persons”, and group three “thirty healthy individuals with normal
body weight”. Serum resistin was higher in diabetic obese individuals than other two groups, and was positively correlated with
body mass index (BMI), insulin resistance, and CRP . In conclusion serum resistin links between the T2DM and inflammation.
Understanding the mechanism by which this link occurs, may help in clarification the role of resistin in the pathogenesis and
treatment of T2DM.

Key words: obesity, resistin, T2DM, inflammation, insulin resistance






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.